The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.
Matthew A. Powell
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Roche/Genentech; Tesaro
Speakers' Bureau - AstraZeneca; Clovis Oncology; Genentech/Roche; Tesaro
Virginia L. Filiaci
Travel, Accommodations, Expenses - Regeneron; VBL Therapeutics
Other Relationship - GOG Foundation; GOG Foundation (I)
Martee Leigh Hensley
Employment - Sanofi (I)
Stock and Other Ownership Interests - Sanofi (I)
Consulting or Advisory Role - comsort; EMD Serono; Janssen; Janssen; Janssen; Janssen; Lilly; Lilly; Lilly; Onclive; Tesaro; Tesaro
Research Funding - Bristol-Myers Squibb (Inst); Johnson & Johnson (Inst)
Patents, Royalties, Other Intellectual Property - author, Up to Date
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Janssen; Janssen; Janssen; Lilly; Tesaro; Tesaro
Helen Q Huang
No Relationships to Disclose
Kathleen N. Moore
Consulting or Advisory Role - Advaxis; Aravive; AstraZeneca; Clovis Oncology; Genentech/Roche; Immunogen; Janssen Oncology; Merck; OncoMed; Pfizer/EMD Serono; Samumed; TESARO; VBL Therapeutics
Speakers' Bureau - AstraZeneca
Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Forty Seven (Inst); Genentech (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
Other Relationship - AstraZeneca
Krishnansu Sujata Tewari
Honoraria - Clovis Oncology; Tesaro
Consulting or Advisory Role - Roche/Genentech
Speakers' Bureau - AstraZeneca; Merck; Roche/Genentech
Research Funding - Abbvie (Inst); Genentech/Roche (Inst); Merck (Inst); Morphotek (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
Larry J. Copeland
Consulting or Advisory Role - Clovis Oncology; Immunogen; Janssen Oncology; Tesaro; Tesaro
Expert Testimony - Johnson & Johnson
Angeles Alvarez Secord
No Relationships to Disclose
David G Mutch
No Relationships to Disclose
Alessandro Santin
No Relationships to Disclose
William Richards
No Relationships to Disclose
David Philip Warshal
No Relationships to Disclose
Nicola M. Spirtos
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst)
Paul Disilverstro
No Relationships to Disclose
Olga Ioffe
No Relationships to Disclose
David S. Miller
Consulting or Advisory Role - Alexion Pharmaceuticals; Alexion Pharmaceuticals; AstraZeneca; Clovis Oncology; Eisai; Genentech; Guardant Health; Guardant Health; Incyte; Janssen; Janssen Oncology; Karyopharm Therapeutics; Merck Sharp & Dohme (Inst); Tesaro
Speakers' Bureau - Clovis Oncology; Genentech
Research Funding - Advaxis (Inst); Advenchen Laboratories (Inst); Aeterna Zentaris (Inst); Immunogen (Inst); Janssen (Inst); Mateon Therapeutics (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Pfizer (Inst); Tesaro (Inst); TRACON Pharma (Inst); US Biotest (Inst); Xenetic Biosciences (Inst)